Pfizer enters deal with Incyte to market CCR2 anti-inflammatory drugs
Pfizer today entered a deal with Incyte Corporation to research, manufacture and market Incyte’s anti-inflammatory CCR2 antagonist drugs.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.